



# Brilliant Violet 510™ anti-human CD69 Antibody

Catalog# / Size 310935 / 25 tests

310936 / 100 tests

Clone FN50

Regulatory Status RUO

Workshop IV A91

Other Names Very Early Activation Antigen (VEA), Activation inducer molecule (AIM)

**Isotype** Mouse IgG1, κ

**Description** CD69 is a 27-33 kD type II transmembrane protein also known as activation inducer molecule

(AIM), very early activation antigen (VEA), and MLR3. It is a member of the C-type lectin family, expressed as a disulfide-linked homodimer. Other members of this receptor family include NKG2, NKR-P1 CD94, and Ly49. CD69 is transiently expressed on activated leukocytes including T cells, thymocytes, B cells, NK cells, neutrophils, and eosinophils. CD69 is

constitutively expressed by a subset of medullary mature thymocytes, platelets, mantle B cells, and certain CD4<sup>+</sup> T cells in germinal centers of normal lymph nodes. CD69 is involved in early events of lymphocyte, monocyte, and platelet activation, and has a functional role in redirected

lysis mediated by activated NK cells.

## **Product Details**

Verified Reactivity Human

Reported Reactivity African Green, Baboon, Chimpanzee, Cynomolgus, Pigtailed Macague, Rhesus

Antibody Type Monoclonal

Host Species Mouse

Formulation Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).

Preparation The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 510™

under optimal conditions.

Concentration Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration

and Expiration Lookup or Certificate of Analysis online tools.)

Storage & Handling The antibody solution should be stored undiluted between 2°C and 8°C, and protected from

prolonged exposure to light. Do not freeze.

Application FC - Quality tested

Recommended Usage Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric

analysis. For flow cytometric staining, the suggested use of this reagent is 5 μl per million cells in

100 μl staining volume or 5 μl per 100 μl of whole blood.

Brilliant Violet 510™ excites at 405 nm and emits at 510 nm. The bandpass filter 510/50 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 510™ is a trademark of Sirigen Group Ltd.

Learn more about Brilliant Violet™.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.

equivalente.

Excitation Laser Violet Laser (405 nm)

#### Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue sections<sup>2</sup>, immunofluorescence microscopy<sup>3</sup>, and spatial biology (IBEX)<sup>8,9</sup>

### Application References

1. Knapp WB, et al. 1989. Leucocyte Typing IV. Oxford University Press. New York.

### (PubMed link indicates BioLegend citation)

- 2. Sakkas LI, et al. 1998. Clin. and Diag. Lab. Immunol. 5:430. (IHC)
- 3. Kim JR, et al. 2005. BMC Immunol. 6:3. (IF)
- 4. Verjans GM, et al. 2007. P. Natl. Acad. Sci. USA 104:3496. 5. Lu H, et al. 2009. Toxicol Sci. 112:363. (FC) PubMed
- 6. Thakral D, et al. 2008. J. Immunol. 180:7431. (FC) PubMed
- 7. Yoshino N, et al. 2000. Exp. Anim. (Tokyo) 49:97. (FC)
- 8. Radtke AJ, et al. 2020. Proc Natl Acad Sci USA. 117:33455-33465. (SB) PubMed
- 9. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed

#### **Product Citations**

- 1. Wenthe J, et al. 2021. Cancer Immunology Immunotherapy. . PubMed
- 2. Glaubitz J, et al. 2022. Nat Commun. 13:4502. PubMed
- 3. Huang B, et al. 2020. Cell. 179(5):1160-1176.e24.. PubMed
- 4. Naaber P, et al. 2022. Cell Rep Med. 3:100716. PubMed
- 5. Vikkurthi R, et al. 2022. Nat Microbiol. 7:974. PubMed

AB\_2563834 (BioLegend Cat. No. 310936)

- 6. Waddington KE, et al. 2020. Front Immunol. 1.51875. PubMed
- 7. Calzoni E, et al. 2019. J Allergy Clin Immunol. 143:2317. PubMed
- 8. Wang J, et al. 2020. Cell. 183(7):1867-1883.e26. PubMed 9. Upasani V, et al. 2019. Front Immunol. 2.152777778. PubMed

RRID AB\_2562282 (BioLegend Cat. No. 310935)

# **Antigen Details**

Structure C-type lectin, type II glycoprotein, 28/32 kD

Distribution Activated T cells, B cells, NK cells, granulocytes, thymocytes, platelets, Langerhans cells

**Function** Lymphocyte, monocyte, and platelet activation, NK cell killing

Cell Type B cells, Granulocytes, Langerhans cells, NK cells, Platelets, T cells, Thymocytes, Tregs

**Biology Area** Costimulatory Molecules, Immunology

Molecular Family **CD Molecules** 

Antigen References 1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.

2. Testi R, et al. 1994. Immunol. Today 15:479.

Gene ID 969


## **Related Protocols**

Cell Surface Flow Cytometry Staining Protocol

# Other Formats

Purified anti-human CD69, FITC anti-human CD69, PE anti-human CD69, PE/Cyanine5 anti-human CD69, APC anti-human CD69, APC/Cyanine7 anti-human CD69, PE/Cyanine7 anti-human CD69, Alexa Fluor® 488 anti-human CD69, Alexa Fluor® 647 antihuman CD69, Pacific Blue™ anti-human CD69, Alexa Fluor® 700 anti-human CD69, Biotin anti-human CD69, PerCP/Cyanine5.5 anti-human CD69, PerCP anti-human CD69, Brilliant Violet 421™ anti-human CD69, Brilliant Violet 785™ anti-human CD69, Brilliant Violet 650™ anti-human CD69, Brilliant Violet 510™ anti-human CD69, Brilliant Violet 605™ anti-human CD69, Purified anti-human CD69 (Maxpar® Ready), PE/Dazzle™ 594 anti-human CD69, Brilliant Violet 711™ anti-human CD69, APC/Fire™ 750 anti-human CD69, TotalSeq™-A0146 anti-human CD69, TotalSeq™-B0146 anti-human CD69, TotalSeq™-C0146 anti-human CD69, Brilliant Violet 750™ anti-human CD69, KIRAVIA Blue 520™ anti-human CD69, Spark NIR™ 685 anti-human CD69 Antibody, PE/Fire™ 640 anti-human CD69, Spark YG™ 581 anti-human CD69, TotalSeq™-D0146 anti-human CD69, Spark Blue™ 550 anti-human CD69

## **Product Data**



Human peripheral blood lymphocytes were stimulated with PMA+ ionomycin for 6 hours and then stained with CD69 (clone FN50) Brilliant Violet 510<sup>TM</sup> (filled histogram) or mouse lgG1, κ Brilliant Violet 510<sup>TM</sup> isotype control (open histogram).

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587